Gregory Hinkle

USPTO Granted Patents = 95 (Patent Applications = 78)

CIPO Patents = 7 (Patent Applications = 19)

EPO Patents = 20 (Patent Applications = 49)

Average Co-Inventor Count = 3.1

ph-index = 10

Forward Citations = 440(Granted Patents)

Inventors with similar research interests:

Location History:

Plymoutth, MA (US) (2018)
Plymouth, MA (US) (2004 - 2024)
Cambridge, MA (US) (2012 - 2024)

Company Filing History:

70 out of 443

Alnylam Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

patents

4. 4 out of 6,954

Monsanto Technology LLC

patents

5. 2 out of 18

Arrowhead Research Corporation

patents

6. 2 out of 1,342

Regeneron Pharmaceuticals, Inc.

Years Active: 2004-2025

Loading Chart...

95 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12359201 - 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof (2025-07-15),

2. 12338439 - Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof (2025-06-24),

3. 12227744 - Compositions and methods for inhibiting expression of transthyretin (2025-02-18),

4. 12091666 - Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof (2024-09-17),

5. 12091661 - Organic compositions to treat HSF1-related diseases (2024-09-17),

6. 12071619 - SERPINA1 iRNA compositions and methods of use thereof (2024-08-27),

7. 12031133 - GNAQ targeted dsRNA compositions and methods for inhibiting expression (2024-07-09),

8. 11987792 - Compositions and methods for inhibiting expression of the LECT2 gene (2024-05-21),

9. 11884919 - Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene (2024-01-30),

10. 11866701 - Complement component C3 iRNA compositions and methods of use thereof (2024-01-09),

11. 11859185 - Glucokinase (GCK) iRNA compositions and methods of use thereof (2024-01-02),

12. 11834661 - Angiotensinogen (AGT) iRNA compositions and methods of use thereof (2023-12-05),

13. 11685918 - Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof (2023-06-27),

14. 11434487 - Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof (2022-09-06),

15. 11419942 - Angiotensinogen (AGT) iRNA compositions and methods of use thereof (2022-08-23),

Title: The Inventor Extraordinaire: Gregory Hinkle

Introduction:

Gregory Hinkle, a prolific inventor hailing from Plymouth, MA (US), has made significant contributions to the field of biotechnology with an impressive portfolio of 87 patents.

Latest Patents:

Among his latest patents are groundbreaking inventions such as *"Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene,"* which focuses on targeting the Serum Amyloid A (SAA) gene using double-stranded ribonucleic acid (dsRNA). Additionally, *"Complement component C3 iRNA compositions and methods of use thereof"* addresses treating various complement component C3-associated diseases using iRNA compositions.

Career Highlights:

Gregory Hinkle's career shines with experience at renowned companies like Alnylam Pharmaceuticals, Inc., and Novartis AG, where he honed his skills and expertise in the biopharmaceutical industry, paving the way for his remarkable inventions.

Collaborations:

Throughout his journey, Gregory Hinkle has collaborated with esteemed colleagues such as Stuart Milstein and Kevin Fitzgerald, shaping innovative solutions and pushing the boundaries of scientific research.

Conclusion:

In conclusion, Gregory Hinkle stands as a beacon of innovation in the biotechnology sector, with a trail of patents that revolutionize the way we approach genetic diseases and therapeutic interventions. His dedication to advancing science underscores his commitment to creating a better future for healthcare and beyond.

This text is generated by artificial intelligence and may not be accurate.